Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States - Understanding the transition to adaptive, ultra-hypofractionated treatments

Authors

Michael D Chuong, Miami Cancer Institute
Lauren E Henke, Washington University School of Medicine in St. Louis
et al.

Journal

Clinical and Translational Radiation Oncology

Publication Date

1-1-2023

Volume

38

First Page

161

Last Page

168

Document Type

Open Access Publication

DOI

10.1016/j.ctro.2022.11.013

Rights and Permissions

Chuong MD, Clark MA, Henke LE, Kishan AU, Portelance L, Parikh PJ, Bassetti MF, Nagar H, Rosenberg SA, Mehta MP, Refaat T, Rineer JM, Smith A, Seung S, Zaki BI, Fuss M, Mak RH. Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States - Understanding the transition to adaptive, ultra-hypofractionated treatments. Clin Transl Radiat Oncol. 2022 Nov 22;38:161-168. doi: 10.1016/j.ctro.2022.11.013. © 2022 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Chuong, Michael D; Henke, Lauren E; and et al., "Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States - Understanding the transition to adaptive, ultra-hypofractionated treatments." Clinical and Translational Radiation Oncology. 38, 161 - 168. (2023).
https://digitalcommons.wustl.edu/oa_4/1464